| scholarly article | Q13442814 |
| P50 | author | Edward M. Sellers | Q38639939 |
| P2093 | author name string | C Bartlett | |
| C M Anderson | |||
| K A Schoedel | |||
| M J Shram | |||
| R L Shazer | |||
| P2860 | cites work | Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 |
| Annual Deaths Attributable to Obesity in the United States | Q22253003 | ||
| Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance | Q28186874 | ||
| Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior | Q28286238 | ||
| Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors | Q28291458 | ||
| Overweight, obesity, and blood pressure: the effects of modest weight reduction | Q33930674 | ||
| Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization | Q34746665 | ||
| Guidelines and methodological reviews concerning drug abuse liability assessment | Q35132177 | ||
| Principles of initial experimental drug abuse liability assessment in humans | Q35132181 | ||
| Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey | Q36024609 | ||
| Assessing abuse liability during drug development: changing standards and expectations. | Q37062910 | ||
| Lipoprotein responses to weight loss and weight maintenance in high-risk obese subjects | Q43963757 | ||
| Patterns of use and harms associated with non-medical ketamine use. | Q44283696 | ||
| Intentional weight loss and mortality among overweight individuals with diabetes | Q47227882 | ||
| Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans. | Q51125173 | ||
| Correlates of objectively measured physical activity in obese children. | Q53127455 | ||
| Research design strategies to evaluate the impact of formulations on abuse liability | Q59488289 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | serotonin | Q167934 |
| lorcaserin hydrochloride hemihydrate | Q27135478 | ||
| lorcaserin hydrochloride | Q27888442 | ||
| P304 | page(s) | 683-692 | |
| P577 | publication date | 2011-03-16 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users | |
| P478 | volume | 89 |
| Q37992857 | A review of late-stage CNS drug candidates for the treatment of obesity |
| Q48120132 | Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users |
| Q57177981 | Centrally Acting Agents for Obesity: Past, Present, and Future |
| Q35049574 | Characterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity |
| Q28973615 | Current approaches for the discovery of drugs that deter substance and drug abuse |
| Q52604833 | Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT2C Receptor. |
| Q46282660 | Effects of lorcaserin (Belviq®) on nicotine- and food-maintained responding in non-human primates |
| Q89308612 | Effects of lorcaserin and buspirone, administered alone and as a mixture, on cocaine self-administration in male and female rhesus monkeys |
| Q58080217 | Effects of lorcaserin on reinstatement of responding previously maintained by cocaine or remifentanil in rhesus monkeys |
| Q46240693 | Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles |
| Q47348330 | Inhibition of cocaine and 3,4-methylenedioxypyrovalerone (MDPV) self-administration by lorcaserin is mediated by 5-HT2C receptors in rats |
| Q98665131 | Learning from lorcaserin: lessons from the negative clinical trial of lorcaserin to treat cocaine use disorder |
| Q36432310 | Lorcaserin Reduces the Discriminative Stimulus and Reinforcing Effects of Cocaine in Rhesus Monkeys |
| Q39186891 | Lorcaserin: A novel antiobesity drug |
| Q38117028 | New obesity agents: lorcaserin and phentermine/topiramate |
| Q30243992 | Obesity: Current and potential pharmacotherapeutics and targets |
| Q47849415 | Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity |
| Q47588598 | Role of impulsivity and reward in the anti-obesity actions of 5-HT2C receptor agonists |
| Q92103068 | Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers |
| Q33874819 | Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction |
| Q36540945 | Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction |
| Q91749643 | Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development |
| Q35837700 | The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control |
| Q47677518 | The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders |
| Q38160636 | The safety and efficacy of lorcaserin in the management of obesity |
| Q91968373 | The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study |
| Q47896293 | Withdrawal assessment following subchronic oral ketamine administration in Cynomolgus macaques |
Search more.